SAB Biotherapeutics, Inc. (SABS) remained unchanged in the premarket after the company updated the Positive Phase 2 Virology Data. However, the last trading session closed at $5.48 with a decrease of 5.84%.
Positive Phase 2 Virology Data – What’s this?
SABS announced the positive phase 2 virology data on 24th January 2022. According to the company, SAB-185 satisfied the requirements for progression to Phase 3 in the US National Institutes of Health (NIH) COVID-19 ACTIV-2 Trial. The Phase 3 ACTIV-2 study is now evaluating SAB-185, a completely human, precisely targeted, broadly neutralizing polyclonal antibody candidate for the treatment of individuals with mild to moderate COVID-19. Moreover, the National Institute of Allergy and Infectious Diseases (NIAID), is sponsoring and conducting the ACTIV-2 studies in partnership with the AIDS Clinical Trials Group in Phase 2 and Phase 3.
SAB-185 may have the potential of COVID-19. Despite an early protocol adjustment that resulted in enrolment mostly of patients at low risk of severe illness, SAB-185 appeared safe and met a key virologic effectiveness criterion, SAB-185 looked to be safe and met a key virologic efficacy criterion. In addition, the initial plan was designed to target high-risk individuals who would benefit the most from SAB-185 therapy. When compared to high-risk placebo controls, data from a small group of high-risk patients treated with SAB-185 revealed dramatic reductions in viral load. Last but not the least, SAB-185 is being evaluated in a high-risk group as part of a Phase 3 investigation.
SAB-185 Retains Neutralization
On 16th December 2022, SABS announced that in an in vitro pseudovirus model, findings showed that SAB-185 retained neutralizing ability against the Omicron SARS-CoV-2 variant. Moreover, scientists from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research compiled the data. These hopeful findings come at a crucial moment, as COVID continues to establish its resiliency in the global human population. Last but not the least, it also adds to the evidence that the polyclonal antibody approach to a highly changing virus-like SARS-CoV-2 might be useful in the treatment of the disease.